Industrial-Tech Fujifilm target price increases by over 77%, Lao Fengxiang rating downgraded | Securities analyst ratings watch

GateUser-bd883c58 · 2026-03-17T06:26:01+00:00

On March 12, securities firms frequently adjusted target prices for listed companies. Industrial Internet of Things, Sunac China Holdings, and Xinli Pharmaceutical saw the largest gains, with increases of 77.01%, 44.26%, and 34.22%, respectively. Chongqing Brewery received recommendations from 4 firms, Sate New Materials' rating was upgraded to "Buy," and Lao Fengxiang's rating was downgraded to "Hold." Additionally, there were 6 initial coverage initiations, all of which assigned "Buy" ratings.

GateUser-bd883c58

2026-03-17 06:26:01

Abstract generation in progress

According to Yue Sheng Investment Research data, on March 12, brokerage firms issued a total of 12 target price updates for listed companies. Based on the latest closing prices, the companies with the highest target price increases are Industrial Fuxin, New City Holdings, and Xinli Tai, with increases of 77.01%, 44.26%, and 34.22%, respectively. These belong to the consumer electronics, real estate development, and chemical pharmaceutical industries.

In terms of the number of brokerage recommendations, on March 12, 28 listed companies received brokerage recommendations. Chongqing Beer received 4 recommendations, while Huali Group and Industrial Fuxin each received 2 recommendations.

Regarding rating upgrades, on March 12, one company’s rating was upgraded. Northeast Securities raised Sate New Material’s rating from “Accumulate” to “Buy.”

Regarding rating downgrades, on March 12, one company’s rating was lowered. Wanlian Securities downgraded Laofengxiang’s rating from “Buy” to “Hold.”

For initial coverage, on March 12, brokerages provided a total of 6 first-time coverage reports. Shanxi Securities gave Zhongchu Media a “Buy” rating; Western Securities gave Jiuli Special Materials a “Buy” rating; Tianfeng Securities gave Shandong Gold a “Buy” rating; Dongwu Securities gave Baicheng Medicine a “Buy” rating; Guojin Securities gave Xinli Tai a “Buy” rating.

Disclaimer: The opinions, data, and individual stocks involved in this article are compiled by Yue Sheng Investment Research analyst Qin Jian (Registration Number A0590622100001) team. They are for reference only and do not constitute investment advice. Investment involves risks; operate cautiously.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.